United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2012_register executive 2012-05-02 article Notices D09002ee1c7fd12e7 D09002ee1c7fd1365 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States Centers for Disease Control and Prevention originator org United States Government Agency or Subagency This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, exclusive license (excluding the nonexclusively licensed field of use entitled "Use of P4 as either a carrier and/or immunoenhancer in a polysaccharide vaccine conjugate for prevention of Streptococcus pneumonia infection in humans") to practice the inventions embodied in the patent application referred to below to Viper Therapeutics, having a place of business in Atlanta, Georgia. The patent rights in these inventions have been assigned to the government of the United States of America. The patent(s) to be licensed are: 77 FR 26014 https://www.govinfo.gov/app/details/FR-2012-05-02/2012-10547 2012-10547 fr02my12-63 4163-18-P https://www.govinfo.gov/app/details/FR-2012-05-02/2012-10547 https://www.govinfo.gov/content/pkg/FR-2012-05-02/html/2012-10547.htm https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10547.pdf 1 p. 26014 26014 77 FR 26014 Prospective Grant of Exclusive License: P4 Peptide From Streptococcus Pneumoniae; Federal Register Vol. 77, Issue NOTICE 2012-10547 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention 4163-18-P 2012-10547 Notice.

This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, exclusive license (excluding the nonexclusively licensed field of use entitled "Use of P4 as either a carrier and/or immunoenhancer in a polysaccharide vaccine conjugate for prevention of Streptococcus pneumonia infection in humans") to practice the inventions embodied in the patent application referred to below to Viper Therapeutics, having a place of business in Atlanta, Georgia. The patent rights in these inventions have been assigned to the government of the United States of America. The patent(s) to be licensed are:

5/19/2005. Prospective Grant of Exclusive Licenses: P4 Peptide from Streptococcus pneumoniae , Vol. 77, no. 85 Office of the Federal Register, National Archives and Records Administration 2012-05-02 continuing daily deposited born digital 298 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2012-05-02 P0b002ee18260a233 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr02my12 https://www.govinfo.gov/app/details/FR-2012-05-02 https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/FR-2012-05-02.pdf https://www.govinfo.gov/content/pkg/FR-2012-05-02/xml/FR-2012-05-02.xml fdlp 25859 26148 DGPO 2012-05-02 2024-06-03 FR-2012-05-02 machine generated eng FR FR-2012-05-02 77 85